Inmune Bio (INMB) EBITDA (2018 - 2026)
Inmune Bio (INMB) posted EBITDA of -$5.8 million for Q1 2026, down 6.17% sequentially from -$5.5 million in Q4 2025, and up 41.32% YoY from -$4.1 million in Q1 2025.
Inmune Bio (INMB) EBITDA (2018 - 2026) Analysis & Trends
Inmune Bio has reported EBITDA for 9 years, with the latest figure at -$5.8 million in Q1 2026.
- Quarterly EBITDA rose 41.32% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.3 million (down 4.26% YoY) and the FY2025 annual result came in at -$47.4 million, down 11.14% from the prior year.
- EBITDA eased to -$5.8 million in Q1 2026 per INMB's latest filing, from -$5.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$5.5 million in Q4 2025 and troughed at -$24.6 million in Q2 2025.
- A 5-year average of -$8.9 million and a median of -$7.4 million in 2022 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 42.18% in 2025, down 149.07% in 2025.
- Over 5 years, EBITDA stood at -$5.6 million in 2022, then slumped by 48.51% to -$8.4 million in 2023, then fell by 12.98% to -$9.5 million in 2024, then jumped by 42.18% to -$5.5 million in 2025, then decreased by 6.17% to -$5.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$5.8 million, -$5.5 million, and -$7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 133.12 Mn |
| 10 | Inmune Bio | 62.01 Mn | 43.60 Mn | - | -1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.48 Mn |
| Mar 31, 2026 | -5.81 Mn |
| Dec 31, 2025 | -5.47 Mn |
| Sep 30, 2025 | -7.43 Mn |
| Jun 30, 2025 | -24.57 Mn |
| Mar 31, 2025 | -9.91 Mn |
| Dec 31, 2024 | -9.47 Mn |
| Sep 30, 2024 | -12.29 Mn |
| Jun 30, 2024 | -9.87 Mn |
| Mar 31, 2024 | -11.02 Mn |
| Dec 31, 2023 | -8.38 Mn |
| Sep 30, 2023 | -8.53 Mn |
| Jun 30, 2023 | -6.41 Mn |
| Mar 31, 2023 | -6.42 Mn |
| Dec 31, 2022 | -5.64 Mn |
| Sep 30, 2022 | -7.44 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -6.48 Mn |
| Dec 31, 2021 | -9.03 Mn |
| Sep 30, 2021 | -9.02 Mn |